The impact of different antibiotic treatment regimens on mortality in Mycobacterium avium complex pulmonary disease: a population-based cohort study

Evidence-based guidelines recommend the combination of macrolide–ethambutol–rifamycin as first-line treatment for Mycobacterium avium complex pulmonary disease (MAC-PD) [1]. Whether this regimen results in improved survival is unknown.

Source: European Respiratory Journal - September 9, 2020 Category: Respiratory Medicine Authors: Brode, S. K., Chung, H., Campitelli, M. A., Kwong, J. C., Sutradhar, R., Marchand-Austin, A., Winthrop, K. L., Jamieson, F. B., Marras, T. K. Tags: Original Articles: Research letters Source Type: research